Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
South Korea, US Set Major Military Drills for August 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
Myanmar Rejects ASEAN Special Envoy, Challenges Regional Peace Plan 
Iran-Oman Hormuz Shipping Deal Nears Final Stage 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
New Zealand MMP Electoral System Faces Fresh Referendum Debate 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Iran-Oman Near Strait of Hormuz Deal as Shipping Tensions Persist 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Novo Nordisk has named U.S. pharmaceutical executive Greg Miley as its new Global Head of Corporate Affairs, a strategic move as the Danish drugmaker faces heightened scrutiny from U.S. President Donald Trump over drug pricing. Miley, formerly Senior Vice President of Government Affairs at AbbVie, announced his appointment on LinkedIn, with Novo Nordisk confirming the news to Reuters.
The company stated that Miley will officially join in early November, overseeing global communications and public affairs. His extensive experience in the U.S. pharmaceutical sector is expected to help Novo strengthen its political and regulatory strategies in its largest market—the United States. A company source noted that Miley’s top priority will be managing relations with the Trump administration, which has recently intensified pressure on pharmaceutical firms to reduce prices.
Miley’s appointment aligns with new CEO Mike Doustdar’s efforts to regain investor confidence through a broad restructuring initiative aimed at improving competitiveness in the growing obesity drug market, particularly against Eli Lilly. The overhaul involves cutting about 9,000 jobs worldwide, including 5,000 in Denmark and several in the U.S.
In his LinkedIn post, Miley expressed optimism about enhancing Novo’s global communication and public affairs, noting his upcoming relocation to Denmark. Industry insiders say other major pharma companies have also been recruiting public affairs experts with strong Republican ties to navigate Washington’s policy landscape.
Shares of Novo Nordisk and Eli Lilly dropped on Friday following Trump’s statement that the price of Ozempic—Novo’s diabetes drug containing the same ingredient as its popular weight-loss drug Wegovy—would be lowered.
Miley brings nearly two decades of experience in pharmaceutical government relations, with past roles at Abbott and Pfizer, making him a pivotal figure in Novo’s next phase of global engagement.
